Cingulate Inc. Financing Cash Flow
Cingulate Inc. (CING) reported Financing Cash Flow of $30.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Cingulate Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $8.48M, a 102.66% increase year-over-year.
- Cingulate Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $21.91M, a 1043.78% increase year-over-year.
- Cingulate Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $8.59M, a 33.17% increase year-over-year.
- Cingulate Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.46M, a 89.08% decline year-over-year.
- Cingulate Inc. net cash provided by (used in) financing activities for fiscal 2025 was $16.15M, a 47.60% decline from fiscal 2024.
- Cingulate Inc. net cash provided by (used in) financing activities for fiscal 2024 was $30.82M, a 209.62% increase from fiscal 2023.
- Cingulate Inc. net cash provided by (used in) financing activities for fiscal 2023 was $9.95M, a 103.20% increase from fiscal 2022.
- Cingulate Inc. net cash provided by (used in) financing activities for fiscal 2022 was $4.90M, a 81.54% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $30.39M 10-Q · filed 2026-08-13 | $38.98M derived: sum of 3 quarters · filed 2026-08-13 | $40.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $21.91M 10-Q · filed 2026-05-14 | $30.50M derived: sum of 2 quarters · filed 2026-05-14 | $31.97M derived: sum of 3 quarters · filed 2026-05-14 | $36.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $10.05M derived: sum of 2 quarters · filed 2026-03-18 | $14.23M derived: sum of 3 quarters · filed 2026-08-13 | $16.15M 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.65M derived: sum of 2 quarters · filed 2026-08-13 | $7.56M 10-Q · filed 2025-11-13 | $14.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.10M 10-Q · filed 2026-08-13 | $12.55M derived: sum of 3 quarters · filed 2026-08-13 | $25.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.92M 10-Q · filed 2026-05-14 | $8.37M derived: sum of 2 quarters · filed 2026-05-14 | $21.77M derived: sum of 3 quarters · filed 2026-05-14 | $22.85M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $19.85M derived: sum of 2 quarters · filed 2026-03-18 | $20.93M derived: sum of 3 quarters · filed 2026-03-18 | $30.82M 10-K · filed 2026-03-18 |
| 2024-09-30 | $13.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $14.48M derived: sum of 2 quarters · filed 2025-11-13 | $24.37M 10-Q · filed 2025-11-13 | $25.19M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $10.97M 10-Q · filed 2025-08-19 | $11.79M derived: sum of 3 quarters · filed 2025-08-19 | $17.71M derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $9.89M 10-Q · filed 2025-05-08 | $10.70M derived: sum of 2 quarters · filed 2025-05-08 | $16.63M derived: sum of 3 quarters · filed 2025-05-08 | $19.85M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $815.43K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.74M derived: sum of 2 quarters · filed 2025-03-27 | $9.96M derived: sum of 3 quarters · filed 2025-03-27 | $9.95M 10-K · filed 2025-03-27 |
| 2023-09-30 | $5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.14M derived: sum of 2 quarters · filed 2024-11-07 | $9.14M 10-Q · filed 2024-11-07 | $9.05M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.21M 10-Q · filed 2024-08-13 | $3.12M derived: sum of 3 quarters · filed 2024-08-13 | $8.12M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.92K 10-Q · filed 2024-05-08 | -$93.70K derived: sum of 2 quarters · filed 2024-05-08 | $4.90M derived: sum of 3 quarters · filed 2024-05-08 | $4.90M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$89.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.91M derived: sum of 2 quarters · filed 2024-04-01 | $4.90M derived: sum of 3 quarters · filed 2024-04-01 | $4.90M 10-K · filed 2024-04-01 |
| 2022-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.99M derived: sum of 2 quarters · filed 2023-11-13 | $4.99M 10-Q · filed 2023-11-13 | $24.90M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$3.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$7.43K 10-Q · filed 2023-08-14 | $19.90M derived: sum of 3 quarters · filed 2023-08-14 | $23.37M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.68K 10-Q · filed 2023-05-10 | $19.91M derived: sum of 2 quarters · filed 2023-05-10 | $23.38M derived: sum of 3 quarters · filed 2023-05-10 | $25.19M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $19.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $23.38M derived: sum of 2 quarters · filed 2023-03-10 | $25.19M derived: sum of 3 quarters · filed 2023-03-10 | $26.54M 10-K · filed 2023-03-10 |
| 2021-09-30 | $3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $5.28M derived: sum of 2 quarters · filed 2022-11-14 | $6.63M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.16M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.35M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $7.97M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |